What Frisium Treats: Main Uses and Benefits

Frisium (Clobazam) is applied as a key component in the management of severe, chronic epilepsy, and is considered relevant in conditions like Lennox-Gastaut Syndrome (LGS) and other forms of intractable epilepsy. The primary indication is the adjunctive treatment of seizures associated with LGS in paediatric and adult patients.

The medication is commonly used to help manage symptoms in conditions characterized by periods of heightened physiological activity, including atonic seizures, tonic seizures, and myoclonic attacks. This therapeutic support supports long-term stability that may help ease the symptom load and persistent burden of these difficult neurological disorders.

Frisium is primarily utilized as an adjunctive stabilizer, meaning it plays a role in managing symptom patterns that require additional supportive relief alongside a patient's primary anti-seizure medications within a comprehensive treatment plan. This approach may assist with achieving a sustained reduction in the total number of recurrent seizures, which contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for High-Risk Manifestations
Primary Symptom Focus	Atonic and tonic seizures (drop attacks).
Typical Context	Chronic, refractory epilepsy syndromes (e.g., LGS).
Patient Benefit	Supports stability and may assist in managing the frequency of events that cause falls, which supports functional stability.

Regulatory References

1. NIH DailyMed Clobazam label

This section summarizes the official population eligibility and non-eligibility information for Frisium (clobazam) as documented in authoritative government regulatory labels.

Populations for Whom Use is Allowed

Use of Frisium is typically approved for patients 2 years of age and older, based on US regulatory labeling. International labels also confirm use in children and adults, often specifying that use in younger children (e.g., between 6 months and 3 years) is restricted to exceptional cases with a compelling medical indication.

Populations For Whom Use is Contraindicated

Frisium is contraindicated and must not be used in individuals with the following conditions, as they represent a high risk of harm:

• Hypersensitivity: Known allergy to clobazam, other benzodiazepines, or any component of the formulation.
• Myasthenia Gravis: Due to the risk of aggravating muscle weakness.
• Severe Organ Impairment: This includes severe respiratory insufficiency, sleep apnoea syndrome, and severe impairment of liver function.
• Substance Abuse History: Individuals with a history of drug or alcohol dependence due to the increased risk of developing dependence.
• Acute Intoxication: Acute intoxication with alcohol or other centrally acting substances.
• Lactation: Use is contraindicated in breastfeeding women due to the drug being excreted in breast milk.

Special Consideration and Restrictions

• Geriatric Patients and those with mild to moderate hepatic impairment require low initial doses and careful monitoring due to increased susceptibility to adverse effects. There is limited experience for patients with severe renal failure.

Interactions with other medicines and products

Frisium (clobazam) has several documented drug and substance interactions, primarily involving effects on the central nervous system (CNS) and metabolic pathways.

---

Pharmacodynamic Interactions

Opioids and CNS Depressants: Concomitant use with opioids or other CNS depressants, including alcohol, is officially restricted due to the risk of profound sedation, respiratory depression, and coma from additive effects. Patients should be advised to abstain from alcohol as it also increases clobazam blood levels by approximately 50%.

---

Pharmacokinetic Interactions

Clobazam's active metabolite, N-desmethylclobazam (NCLB), is a key focus of metabolic interactions:

• CYP2C19 Inhibition: NCLB is metabolized by the enzyme CYP2C19. Co-administration with strong or moderate CYP2C19 inhibitors (e.g., fluconazole, stiripentol, or cannabidiol (CBD)) results in significantly increased exposure (AUC/Cmax) of NCLB. This interaction requires monitoring and dosage adjustments.
• CYP2D6 Inhibition: Clobazam is a weak inhibitor of CYP2D6. Co-administered drugs primarily metabolized by this enzyme (e.g., dextromethorphan) may see an increase in their plasma concentrations, requiring a potential dose reduction of the co-administered drug.

---

Population Considerations

CYP2C19 Poor Metabolizers (PMs) are known to have significantly higher NCLB concentrations than normal metabolizers. This is an official factor used to determine the initial dosage.

Frisium, which is clobazam, is a lipophilic compound that readily crosses the blood-brain barrier. Its primary biological target is the GABAA receptor in the central nervous system, particularly concentrating in brain tissue. Frisium functions as a positive allosteric modulator at the benzodiazepine binding site, which is located at the interface of the GABAA receptor's alpha (alpha) and gamma (gamma) subunits.

Binding of clobazam or its active metabolite, N-desmethylclobazam, modifies the receptor's conformation. This allosteric interaction increases the affinity of the GABAA receptor for the inhibitory neurotransmitter, GABA. The subsequent binding of GABA to its orthosteric site results in a more frequent opening of the receptor's intrinsic chloride ion channel.

This enhanced flux of negatively charged chloride ions ( Cl^-) into the postsynaptic neuron leads to hyperpolarization of the neuronal membrane. The hyperpolarization elevates the threshold required to initiate an action potential, which in turn reduces the excitability and firing frequency of neurons. The system-level physiological consequence of this downstream cascade is generalized central nervous system depression, which modulates the propagation of aberrant neuronal firing.

How to Use Frisium

Frisium (clobazam) is formulated for oral administration and is generally used as part of a long-term treatment plan. The medication is available as a tablet, an oral suspension (liquid), and, in some regions, an oral film, allowing for flexibility in its proper administration.

Administration Details and Dosing Regimens

Category	Instruction Summary
Route of Administration	Oral. Tablets can be taken whole, broken in half, or crushed and mixed with soft food like applesauce. Oral film is placed on the tongue to dissolve without liquid.
Timing in Relation to Meals	Clobazam can be administered with or without food.
Dosing Schedule	Therapy begins with a low starting dose (e.g., 5 mg or 10 mg daily), followed by gradual dose increases (titration). Doses should be increased no more rapidly than once every seven days to reach the target maintenance dose.
Frequency Pattern	Doses greater than 5 mg per day are typically administered in divided doses, twice daily. For split doses, the larger portion is typically administered at bedtime.

Population-Specific Use and Discontinuation

For specific groups, dose adjustments are utilized. Older adults and patients with mild to moderate hepatic impairment generally require a lower starting dose (e.g., 5 mg per day) and a significantly slower titration schedule (often titrating to half the standard dose).

If the medication must be discontinued, the process involves a gradual dose reduction (tapering). This is achieved by decreasing the total daily dose slowly over a period of time, typically by 5 to 10 mg/day on a weekly basis, to comply with proper procedural use.

Frisium, which contains the active ingredient clobazam, is a 1,5-benzodiazepine primarily studied and indicated as an adjunctive (add-on) treatment for specific seizure disorders.

Efficacy in Lennox-Gastaut Syndrome (LGS)

The majority of recent authoritative clinical evidence for clobazam focuses on its use in LGS, a severe form of childhood-onset epilepsy.

• Controlled Trials: Two major randomized, placebo-controlled clinical trials formed the basis for the drug's approval in LGS. These trials investigated the effect of clobazam as an add-on therapy on the weekly frequency of seizures, particularly drop seizures (atonic, tonic, or myoclonic seizures that cause a patient to fall).
• Quantitative Findings: In these trials, patients receiving clobazam experienced numerically greater reductions in weekly drop seizure frequency compared to those receiving placebo. For instance, data collected during the maintenance phase showed median reductions in weekly drop seizures ranging from approximately 41% to over 60%, depending on the dosage used.
• Long-Term Follow-up: Long-term open-label extension studies, following the initial controlled trials, have observed that the reduction in seizure frequency associated with clobazam was generally sustained over periods of one year or more in many patients with LGS.

Investigational and Other Uses

Beyond its primary indication, clobazam has been the subject of research in other areas:

• Other Epilepsy Syndromes: Studies have examined clobazam's use as adjunctive therapy for refractory (treatment-resistant) seizures in patients with other epilepsy syndromes, including Dravet syndrome and refractory focal epilepsy.
• Anxiety: Historically, clobazam was utilized for the short-term relief of severe anxiety, and some evidence suggests it may cause less objective sedation or psychomotor impairment compared to other benzodiazepines. However, its primary clinical focus remains on seizure management.

Common questions about Frisium (FAQ)

Q: Is Frisium used for all types of seizures?

No. The medication has a specific indication from regulatory agencies. It is approved as an add-on treatment for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Q: Does Frisium work immediately or does it need time to build up in the system?

The medication has a relatively fast onset of action, reaching peak concentration in the blood within 0.5 to 4 hours after taking a dose. However, official dosing instructions require a gradual dose increase (titration) and it is used as part of a long-term treatment plan to achieve sustained stabilization.

Q: Is Frisium used as a preventative medication or for acute episodes?

Regulatory documents designate the medication's duration of treatment as Chronic. It is indicated as an adjunctive therapy for a chronic seizure disorder, which means it is intended for long-term management and stabilization rather than for acute, single-use episodes.

Q: Can taking Frisium lead to changes in appetite or weight?

Official product information indicates that changes in appetite have been reported as a potential side effect in clinical trials. Some patients reported an increase in appetite, while others experienced a decrease in appetite. Changes in appetite are generally listed among the reported adverse events.

Q: How long do the initial side effects of Frisium usually last?

According to regulatory guidance, side effects related to the Central Nervous System (CNS), such as sleepiness or sedation, are often most noticeable at the start of treatment or when the dose is being changed. These initial effects may become less pronounced over time as the body adapts to the presence of the medication.

Q: Should I limit caffeine intake while taking Frisium?

While there is no specific regulatory restriction or warning against caffeine consumption, official prescribing information advises that the provider be informed of all supplements, foods, and drinks consumed. This allows for assessment related to the medication's general interaction profile.

Q: Does Frisium interact with common vitamins?

Official labeling advises that the healthcare provider be notified of all vitamins, minerals, and dietary supplements being used. This is a general safety measure that allows the professional to monitor for any potential interactions, though specific interactions with common vitamins are often not explicitly cited.

Q: What happens if I forget to take my Frisium dose?

Official patient information includes guidance for missed doses. If a dose is missed, the guidance states that the dose is taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the regulatory recommendation is to skip the missed dose and resume the regular schedule. The guidance is that doses are not doubled.

Q: How long does the effect of one dose of Frisium typically last?

Pharmacokinetic data from official sources describes the duration of the medication's effect through its long half-life. Clobazam and its active metabolite remain in the body for an extended time, with elimination half-lives ranging from approximately 36 to 82 hours. This characteristic contributes to a need for sustained and consistent administration.

Q: Does tolerance build up when using Frisium long-term?

Regulatory documents acknowledge that with the long-term use of benzodiazepines like clobazam, there is a risk of developing tolerance, where the antiepileptic effect may lessen over time. Official warnings also note the potential for physical dependence and severe withdrawal reactions upon discontinuation.

Q: What should be monitored while taking Frisium?

Patients are officially monitored for certain risks, particularly serious skin reactions (such as SJS or TEN) in the first eight weeks of treatment. Monitoring and dose adjustments are also necessary for individuals with certain factors like mild to moderate liver impairment or specific genetic profiles (CYP2C19 poor metabolizers).

Q: When did Clobazam become available for patient use?

The active ingredient, clobazam, has been available for patient use under various brand names globally for many years. However, the U.S. FDA specifically approved the brand name Onfi for the treatment of seizures associated with Lennox-Gastaut syndrome in October 2011.

Q: Are there other names for Frisium tablets in different countries?

Yes, the active ingredient clobazam is marketed under several other brand names in different countries. The regulatory references list names such as Onfi and Urbanyl as common international equivalents.

Q: Why is Frisium often prescribed when other medications have failed?

Official information indicates that the medication is primarily indicated for seizures associated with Lennox-Gastaut syndrome (LGS), which is known to be a severe and often treatment-resistant form of epilepsy. Its use is often discussed in contexts where patients require adjunctive therapy to stabilize abnormal neuronal firing.

Q: Are there over-the-counter medicines to avoid while taking Frisium?

Caution is advised regarding any over-the-counter (OTC) medicine that may enhance the Central Nervous System (CNS) depressant effects of clobazam. The regulatory advisory recommends that all OTC products, particularly those that cause sleepiness or dizziness (such as certain antihistamines or pain relievers), be reviewed with a healthcare professional.

Q: Does Frisium interact with common antidepressants?

Yes. Official regulatory labeling indicates that clobazam may interact with other medications, including some antidepressants, that are metabolized by the same liver enzymes (CYP450). This type of interaction can alter the concentration of either medication in the blood, potentially requiring monitoring and dose adjustments.

Q: Are there any known herbal supplements that interact with Frisium?

Official labeling advises that the healthcare provider be notified of all herbal products and supplements being used due to the risk of interactions. For example, the regulatory data notes that products containing Cannabidiol (CBD) are known to interact with the liver enzymes responsible for metabolizing clobazam, which may lead to significantly increased exposure to the active metabolite.

Q: Is Frisium meant to be a permanent treatment?

For the treatment of seizures associated with Lennox-Gastaut syndrome, the duration of treatment is officially designated as Chronic in the regulatory documents. This means the medication is intended for long-term, sustained use as part of a patient's overall management plan.

Q: Is Frisium use discouraged for people with certain mental health conditions?

Official regulatory documents list a history of drug or alcohol dependence as a contraindication (a condition that makes use unsafe). Additionally, regulatory warnings note that the medication may worsen existing depression, and monitoring for new or worsening mental health symptoms is required.

Q: What are the official guidelines about Frisium use during pregnancy or breastfeeding?

Use during pregnancy is considered when the potential benefit to the mother is determined to justify the potential risks to the fetus, as the medication may be associated with fetal malformations and neonatal withdrawal. Furthermore, use is contraindicated (must not be used) in women who are breastfeeding, as the medication is known to be excreted in human milk.

Q: Does Frisium affect performance tasks like driving or operating machinery?

Yes. Due to its classification as a Central Nervous System (CNS) depressant, the official labeling includes a safety constraint. The official labeling constrains activities such as driving, operating heavy machinery, or performing other hazardous tasks until sufficient experience is gained with the medication's effects.

Q: What does research say about the long-term safety profile of Frisium?

Studies and official warnings address the long-term profile by noting that there is a risk of developing physical dependence and severe withdrawal reactions associated with extended use. Research evidence from open-label trials has also shown that the seizure reduction effects can be sustained for periods exceeding one year in many patients.

How to Store and Dispose of Frisium (Clobazam)

Storage Requirements

Frisium (clobazam) tablets must be stored in a cool, dry place where the temperature stays below 30°C. Some regulatory labeling specifies that the temperature should not be stored above 25 C. To protect the medicine's stability, the tablets must remain in the original blister pack until the time of administration. It is a mandatory requirement to Keep the product out of the reach and sight of children.

Disposal Instructions

Clobazam is classified as a controlled substance, and its disposal must follow official protocols. The preferred method for discarding unused medicine is via an authorized drug take-back program. If this option is unavailable, the medicine is not recommended for disposal by flushing.

When disposing of the tablets in household trash, they must first be mixed with an undesirable substance (like coffee grounds or dirt), sealed in a container, and then placed in the trash. All disposal must be done in accordance with local requirements.